Antipsychotic use in pregnancy and risk of attention/deficit-hyperactivity disorder and autism spectrum disorder : a Nordic cohort study

dc.contributor.authorHálfdánarson, Óskar
dc.contributor.authorCohen, Jacqueline M.
dc.contributor.authorKarlstad, Øystein
dc.contributor.authorCesta, Carolyn E.
dc.contributor.authorBjørk, Marte Helene
dc.contributor.authorHåberg, Siri Eldevik
dc.contributor.authorEinarsdóttir, Kristjana
dc.contributor.authorFuru, Kari
dc.contributor.authorGissler, Mika
dc.contributor.authorHjellvik, Vidar
dc.contributor.authorKieler, Helle
dc.contributor.authorLeinonen, Maarit K.
dc.contributor.authorNørgaard, Mette
dc.contributor.authorÖztürk Essen, Buket
dc.contributor.authorUlrichsen, Sinna Pilgaard
dc.contributor.authorReutfors, Johan
dc.contributor.authorZoega, Helga
dc.contributor.departmentFaculty of Medicine
dc.date.accessioned2025-11-20T09:00:34Z
dc.date.available2025-11-20T09:00:34Z
dc.date.issued2022-05-01
dc.descriptionPublisher Copyright: © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.en
dc.description.abstractBACKGROUND: Antipsychotics are increasingly used among women of childbearing age and during pregnancy. OBJECTIVE: To determine whether children exposed to antipsychotics in utero are at increased risk of attention-deficit/hyperactivity disorder (ADHD) or autism spectrum disorder (ASD), accounting for maternal diagnoses of bipolar, psychotic and other psychiatric disorders. Design Population-based cohort study, including a sibling analysis. Setting Nationwide data on all pregnant women and their live-born singletons in Denmark (1997-2017), Finland (1996-2016), Iceland (2004-2017), Norway (2004-2017), and Sweden (2006-2016). Participants 4 324 086 children were eligible for inclusion to the study cohort. Intervention Antipsychotic exposure in utero, assessed by pregnancy trimester, type of antipsychotic, and varying patterns of use. Main outcome measures Non-mutually exclusive diagnoses of ADHD and ASD. We used Cox proportional hazard models to calculate hazard ratios (HRs) controlling for maternal psychiatric disorders and other potential confounding factors. FINDINGS: Among 4 324 086 singleton births, 15 466 (0.4%) were exposed to antipsychotics in utero. During a median follow-up of 10 years, we identified 72 257 children with ADHD and 38 674 children with ASD. Unadjusted HRs were raised for both outcomes but shifted substantially towards the null after adjustment; 1.10 (95%CI 1.00 to 1.27) for ADHD and 1.12 (0.97 to 1.29) for ASD. Adjusted HRs remained consistent by trimester of exposure and type of antipsychotic. Comparing in utero exposure with pre-pregnancy use yielded HRs of 0.74 (0.62 to 0.87) for ADHD and 0.88 (0.70 to 1.10) for ASD. Sibling analyses yielded HRs of 1.14 (0.79 to 1.64) for ADHD and 1.34 (0.75 to 2.39) for ASD. DISCUSSION: Our findings suggest little or no increased risk of child ADHD or ASD after in utero exposure to antipsychotics. CLINICAL IMPLICATIONS: Results regarding child neurodevelopment are reassuring for women who need antipsychotics during pregnancy.en
dc.description.versionPeer revieweden
dc.format.extent9
dc.format.extent1295605
dc.format.extent54-62
dc.identifier.citationHálfdánarson, Ó, Cohen, J M, Karlstad, Ø, Cesta, C E, Bjørk, M H, Håberg, S E, Einarsdóttir, K, Furu, K, Gissler, M, Hjellvik, V, Kieler, H, Leinonen, M K, Nørgaard, M, Öztürk Essen, B, Ulrichsen, S P, Reutfors, J & Zoega, H 2022, 'Antipsychotic use in pregnancy and risk of attention/deficit-hyperactivity disorder and autism spectrum disorder : a Nordic cohort study', Evidence-Based Mental Health, vol. 25, no. 2, pp. 54-62. https://doi.org/10.1136/ebmental-2021-300311en
dc.identifier.doi10.1136/ebmental-2021-300311
dc.identifier.issn1362-0347
dc.identifier.other68599658
dc.identifier.other9f068c55-8f66-4312-9c2f-cabb0b4739be
dc.identifier.other85127661943
dc.identifier.other34810174
dc.identifier.urihttps://hdl.handle.net/20.500.11815/6967
dc.language.isoen
dc.relation.ispartofseriesEvidence-Based Mental Health; 25(2)en
dc.relation.urlhttps://www.scopus.com/pages/publications/85127661943en
dc.rightsinfo:eu-repo/semantics/openAccessen
dc.subjectadult psychiatryen
dc.subjectchild & adolescent psychiatryen
dc.subjectpsychiatryen
dc.subjectschizophrenia & psychotic disordersen
dc.subjectAutism Spectrum Disorder/chemically induceden
dc.subjectHumansen
dc.subjectAttentionen
dc.subjectMaleen
dc.subjectAntipsychotic Agents/adverse effectsen
dc.subjectPregnancyen
dc.subjectPrenatal Exposure Delayed Effects/chemically induceden
dc.subjectFemaleen
dc.subjectAttention Deficit Disorder with Hyperactivity/drug therapyen
dc.subjectChilden
dc.subjectCohort Studiesen
dc.subjectPsychiatry and Mental Healthen
dc.titleAntipsychotic use in pregnancy and risk of attention/deficit-hyperactivity disorder and autism spectrum disorder : a Nordic cohort studyen
dc.type/dk/atira/pure/researchoutput/researchoutputtypes/contributiontojournal/articleen

Skrár

Original bundle

Niðurstöður 1 - 1 af 1
Nafn:
54.full.pdf
Stærð:
1.24 MB
Snið:
Adobe Portable Document Format

Undirflokkur